Recombinant Macaca mulatta Neutrophil defensin 3

What is Macaca mulatta Neutrophil defensin 3 and how does it compare to human neutrophil defensins?

Macaca mulatta Neutrophil defensin 3 is an antimicrobial peptide belonging to the α-defensin family produced by neutrophils in rhesus monkeys. These peptides are part of the innate immune system's first line of defense against microbial invasions. Research has demonstrated high homology between defensins in humans and M. mulatta, suggesting similar innate immune responses in nonhuman primates and humans . While human neutrophils typically express neutrophil defensins HNP-1 to HNP-3, studies have shown that M. mulatta possesses seven α-defensins in leukocyte granules - four highly similar to human HNP-1 to HNP-3 and three more similar to human enteric HD-5 . This makes M. mulatta a valuable model for studying human immune responses.

What methods are commonly used for extraction and purification of recombinant Macaca mulatta Neutrophil defensin 3?

The extraction and purification of recombinant Macaca mulatta Neutrophil defensin 3 typically follows similar protocols to other mammalian defensins. Based on established protocols for defensin isolation, researchers commonly employ:

• Recombinant expression in E. coli systems, similar to mouse beta-Defensin 3 protein production

• Purification via high-performance liquid chromatography (HPLC)

• Verification through mass spectrometry to confirm peptide identity

For genomic analysis prior to recombinant production, researchers have successfully extracted genomic DNA from M. mulatta using methods like the Chelex-100 method, followed by PCR amplification using primers designed based on conserved defensin sequences . Sequencing both DNA strands can be performed using technologies such as the BigDye Terminator Reaction kit to verify the correct sequence before recombinant expression .

How does Recombinant Macaca mulatta Neutrophil defensin 3 interact with viral pathogens compared to mosquito defensins?

The interaction between Macaca mulatta Neutrophil defensin 3 and viral pathogens differs significantly from mosquito defensins. While mosquito defensins have been shown to enhance Japanese Encephalitis Virus (JEV) infection by binding to the ED III domain of the viral E protein and promoting virus adsorption to target cells , mammalian defensins typically demonstrate antiviral properties.

Mosquito defensins can accelerate virus entry by interacting with lipoprotein receptor-related protein 2 (LRP2) . In contrast, mammalian neutrophil defensins generally disrupt viral envelopes or interfere with receptor-mediated entry. The distinct evolutionary paths of insect versus primate defensins likely explain these opposing effects on viral pathogens.

Research comparing the specific antiviral activities of recombinant M. mulatta defensins with human counterparts may provide valuable insights into the evolution of innate immunity against viral pathogens in primates.

What is the potential of Macaca mulatta Neutrophil defensin 3 as a biomarker in immunotherapy response prediction?

Recent research has demonstrated that human neutrophil defensins 1, 2, and 3 serve as potential biomarkers for predicting response to anti-PD-(L)1 immunotherapy in non-small cell lung cancer (NSCLC) patients . Mass spectrometry imaging and immunohistochemical analyses have shown that neutrophil defensin expression is significantly associated with positive immunotherapy response .

Studies have revealed a statistical correlation where NSCLC patients can be categorized as immunotherapy responders when at least 2% of tumor cells (p = 0.01) or immune cells (p = 0.043) express neutrophil defensins . Furthermore, patients showing expression of neutrophil defensins demonstrated longer time to disease progression, with a hazard ratio of 0.37 .

While these studies focused on human defensins, the high homology between human and M. mulatta defensins suggests similar potential for M. mulatta Neutrophil defensin 3 as a biomarker in primate models of immunotherapy response. This represents a promising area for translational research using recombinant M. mulatta Neutrophil defensin 3 to develop and validate immunotherapy response biomarkers.

How do genomic variations in Macaca mulatta Neutrophil defensin 3 impact its antimicrobial efficacy against different bacterial strains?

The genomic organization of defensins in Macaca mulatta appears more complex than initially thought. Studies suggest that M. mulatta may possess more defensin genes than humans, potentially as an adaptation to different environmental pathogens . While specific data on Neutrophil defensin 3 variations is limited, research on β-defensins in M. mulatta has shown remarkable conservation within the species, with no intraspecific variability observed in studied populations .

The antimicrobial efficacy of defensins is directly related to their structural characteristics, particularly the spatial arrangement of cationic and hydrophobic residues. Even minor variations in amino acid sequence can significantly alter antimicrobial spectrum and potency. Comparative studies examining defensin efficacy across different bacterial strains would need to account for:

• Bacterial membrane composition differences

• Resistance mechanisms in target pathogens

• Environmental factors affecting defensin activity

Research using recombinant M. mulatta Neutrophil defensin 3 against various bacterial isolates would help establish a comprehensive antimicrobial profile specific to this defensin variant.

What are the optimal conditions for expressing and formulating Recombinant Macaca mulatta Neutrophil defensin 3?

Based on established protocols for similar defensins, the optimal conditions for expressing and formulating Recombinant Macaca mulatta Neutrophil defensin 3 would include:

Expression System:

• E. coli expression systems are commonly used for recombinant defensin production

• Expression constructs should include the mature peptide sequence (typically starting from the first amino acid after the signal peptide)

Purification Strategy:

• Initial capture using affinity chromatography (His-tag systems common)

• Secondary purification via reverse-phase HPLC

• Final polishing step using ion exchange chromatography

Formulation Parameters:
Similar to mouse beta-Defensin 3 protein, optimal formulation would likely include:

• Lyophilization from a 0.2 μm filtered solution in HCl

• Storage at -20°C to -80°C

• Reconstitution in sterile water or buffer at pH 4-6

Activity Verification:

• Antimicrobial assays against standard bacterial strains

• Structural verification via circular dichroism spectroscopy

• Mass spectrometry confirmation of molecular weight

What experimental design is recommended for investigating the immunomodulatory effects of Recombinant Macaca mulatta Neutrophil defensin 3?

An effective experimental design for investigating the immunomodulatory effects of Recombinant Macaca mulatta Neutrophil defensin 3 would include the following components:

In Vitro Studies:

• Immune Cell Activation Assays

  • Peripheral blood mononuclear cells (PBMCs) from both M. mulatta and human sources

  • Flow cytometry analysis of activation markers (CD69, CD86, etc.)

  • Cytokine profiling (IL-6, TNF-α, IL-1β, IL-10)

• Chemotaxis Assays

  • Neutrophil and monocyte migration in response to defensin gradients

  • Comparison with established chemoattractants (IL-8, fMLP)

• Gene Expression Analysis

  • RNA-seq of immune cells exposed to the defensin

  • Focus on immune signaling pathways and inflammatory mediators

In Vivo Studies:

• M. mulatta Model

  • Local and systemic administration of the recombinant defensin

  • Tissue analysis for immune cell infiltration

  • Cytokine profiling in blood and tissue samples

• Infection Challenge Models

  • Pre-treatment with defensin followed by bacterial/viral challenge

  • Assessment of pathogen clearance and inflammatory responses

Control Conditions:

• Vehicle controls (buffer only)

• Human neutrophil defensin 3 for comparative analysis

• Scrambled peptide controls with similar physicochemical properties

This experimental framework would provide comprehensive insights into both the direct and indirect immunomodulatory effects of Recombinant Macaca mulatta Neutrophil defensin 3.

How can Recombinant Macaca mulatta Neutrophil defensin 3 be effectively detected and quantified in biological samples?

For effective detection and quantification of Recombinant Macaca mulatta Neutrophil defensin 3 in biological samples, researchers can employ several complementary techniques:

Immunohistochemistry (IHC):
Based on protocols for human neutrophil defensins, the following procedure is recommended:

• Fixation and processing of tissue samples (FFPE)

• Antigen retrieval using citrate buffer (pH 6) at 96°C for 20 min

• Blocking with normal horse serum (2.5%)

• Incubation with anti-defensin primary antibody (1/100 dilution)

• HRP-conjugated secondary antibody and DAB substrate for visualization

• Threshold setting at moderate staining intensity to account for background

Mass Spectrometry:

• Mass spectrometry imaging (MSI) for tissue localization

• Sample preparation through either:

  • Direct tissue analysis after matrix application

  • Peptide extraction followed by MALDI-TOF MS analysis

• Identification based on molecular weight and fragmentation pattern

ELISA-based Quantification:

• Development of sandwich ELISA using antibodies with specificity for M. mulatta Neutrophil defensin 3

• Standard curves using purified recombinant protein

• Sample preparation through acid extraction techniques optimized for defensin recovery

Western Blot Analysis:

• Tricine-SDS-PAGE for optimal separation of low molecular weight peptides

• Transfer to PVDF membranes (preferred over nitrocellulose for small peptides)

• Blocking with 5% milk or BSA

• Detection with specific anti-defensin antibodies

PCR-based Methods for Expression Analysis:

• RNA extraction with specialized protocols for small tissue samples

• Reverse transcription and qPCR using primers specific to M. mulatta Neutrophil defensin 3

• Normalization to appropriate housekeeping genes

How can Recombinant Macaca mulatta Neutrophil defensin 3 be utilized in studying cancer immunotherapy responses?

Recombinant Macaca mulatta Neutrophil defensin 3 offers valuable opportunities for studying cancer immunotherapy responses, particularly given the emerging evidence linking neutrophil defensins to immunotherapy outcomes . Research applications include:

Predictive Biomarker Development:
Human neutrophil defensins have been identified as potential predictive biomarkers for anti-PD-(L)1 immunotherapy response in NSCLC patients . Studies have shown significantly different expression patterns between responders and non-responders, with statistical analysis revealing that patients can be categorized as responders when at least 2% of tumor cells (p = 0.01) or immune cells (p = 0.031) show neutrophil defensin expression . The high homology between human and M. mulatta defensins suggests similar potential for M. mulatta models.

Mechanism of Action Studies:
Investigating how defensins influence the tumor microenvironment:

• Effects on tumor-infiltrating lymphocytes and myeloid cells

• Modulation of PD-L1 expression on tumor cells

• Alterations in cytokine/chemokine profiles within the tumor

Combinatorial Therapy Approaches:
Given that neutrophil defensins have demonstrated anticancer activity and act as inducers of tumor necrosis , researchers can explore combinatorial approaches using:

• Recombinant defensin administration alongside checkpoint inhibitors

• Defensin gene therapy to enhance local production

• Defensin-based adjuvants for cancer vaccines

Resistance Mechanism Investigations:
Homozygous deletion of defensin genes has been associated with immunotherapy resistance , making recombinant defensins valuable tools for studying:

• Genetic alterations affecting defensin expression in resistant tumors

• Epigenetic regulation of defensin genes

• Defensin signaling pathway disruptions in resistant tumors

What are the current challenges in translating research findings from Macaca mulatta defensins to human therapeutic applications?

Despite the promising research potential, several challenges exist in translating findings from Macaca mulatta defensins to human therapeutic applications:

Structural and Functional Differences:
While high homology exists between M. mulatta and human defensins, studies on β-defensin 2 revealed 22% amino acid differences, primarily in functional regions . These differences may result in varied:

• Antimicrobial specificity and potency

• Receptor binding and signaling effects

• Immunomodulatory properties

Production and Stability Issues:
Defensins present challenges for pharmaceutical development:

• Complex disulfide bond formation requiring proper folding

• Potential aggregation during production and storage

• Susceptibility to proteolytic degradation in vivo

Delivery Challenges:
As cationic peptides, defensins face delivery challenges:

• Binding to serum proteins reducing bioavailability

• Poor tissue penetration due to size and charge

• Limited oral bioavailability necessitating alternative routes

Regulatory Considerations:
Translational research faces regulatory hurdles:

• Need for comprehensive toxicology studies in multiple species

• Immunogenicity concerns with non-human peptide sequences

• Manufacturing consistency requirements for peptide therapeutics

Knowledge Gaps:
Significant knowledge gaps remain:

• Incomplete understanding of defensin receptor interactions across species

• Limited data on pharmacokinetics and pharmacodynamics

• Uncertainty about optimal dosing regimens and administration schedules

Research strategies addressing these challenges could accelerate translation, including:

• Structure-function studies identifying critical regions for activity

• Development of stabilized formulations or defensin mimetics

• Targeted delivery systems enhancing bioavailability

• Comprehensive comparative studies between species

How might studying Recombinant Macaca mulatta Neutrophil defensin 3 contribute to broader understanding of innate immunity evolution?

The study of Recombinant Macaca mulatta Neutrophil defensin 3 offers unique insights into the evolution of innate immunity across primate species. Several research avenues could contribute to this understanding:

Comparative Genomics and Phylogenetics:
Research suggests that M. mulatta may possess more defensin genes than humans . Comprehensive genomic analysis could reveal:

• Evolutionary patterns of gene duplication and diversification

• Selection pressures driving defensin evolution in different primate lineages

• Correlation between defensin repertoire and pathogen exposure history

Functional Conservation and Divergence:
Despite high sequence homology, functional differences may exist between defensins of different species. Studies comparing:

• Antimicrobial activity against ancestral and modern pathogens

• Immunomodulatory effects across primate species

• Receptor binding specificities and downstream signaling

could provide insights into how selective pressures have shaped defensin function through evolutionary time.

Host-Pathogen Co-evolution:
Defensins represent a crucial interface in host-pathogen interactions. Research exploring:

• Pathogen resistance mechanisms against different primate defensins

• Adaptations in defensin structure countering microbial evasion strategies

• Geographical variation in defensin efficacy against regional pathogens

would illuminate co-evolutionary dynamics between primates and their microbial challenges.

What novel analytical techniques could enhance research on Recombinant Macaca mulatta Neutrophil defensin 3?

Emerging analytical techniques hold promise for advancing research on Recombinant Macaca mulatta Neutrophil defensin 3:

Advanced Imaging Technologies:

• Super-resolution microscopy for visualizing defensin interactions with microbial and mammalian cell membranes

• Cryo-electron microscopy for structural analysis of defensin-receptor complexes

• Advanced MALDI-MSI with improved spatial resolution for defensin distribution in tissues

Systems Biology Approaches:

• Multi-omics integration combining transcriptomics, proteomics, and metabolomics to comprehensively map defensin effects

• Network analysis identifying key nodes in defensin signaling pathways

• Machine learning algorithms predicting defensin activities based on sequence and structural features

Single-Cell Technologies:

• Single-cell RNA-seq for heterogeneous responses to defensin exposure

• Mass cytometry (CyTOF) for detailed immune cell phenotyping after defensin treatment

• Microfluidic systems for real-time analysis of defensin effects on individual cells

Structural Biology Innovations:

• Hydrogen-deuterium exchange mass spectrometry for dynamics of defensin-target interactions

• Solid-state NMR for membrane-bound defensin conformations

• Molecular dynamics simulations predicting species-specific defensin interactions

These advanced techniques could provide unprecedented insights into the molecular mechanisms, structural dynamics, and cellular effects of M. mulatta Neutrophil defensin 3, facilitating comparative studies with human defensins and accelerating therapeutic applications.